A novel effect of eicosapentaenoic acid: improved diaphragm strength in endotoxemia

Respiratory muscle weakness is commonplace in critically ill patients, impairing the ability of those patients to breath, prolonging the need for ventilatory support, and increasing the likelihood of respiratory failure when that support is removed. Infections and endotoxemia reduce respiratory muscle strength, probably acting through several mechanisms. It is reported that the omega-3 fatty acid eicosapentaenoic acid (EPA) attenuates the loss in diaphragm specific force generation (that is, diaphragm strength) induced by bacterial endotoxin treatment in rats. EPA is found in fish oils. EPA reduces calpain activation, suggesting a specific effect on this proteolytic pathway. It will be important to identify whether this effect occurs in patients receiving EPA.

Respiratory muscle weakness is commonplace in critically ill patients, impairing the ability of those patients to breath, prolonging the need for ventilatory support, and increasing the likelihood of respiratory failure when that support is removed. Infections and endotoxemia reduce respiratory muscle strength, probably acting through several mechanisms -including increased oxidative stress, caspase activation leading to protein breakdown, and activation of the proteasome and calpain proteolytic systems resulting in protein loss. Supinski and colleagues report that the omega-3 fatty acid eicosapentaenoic acid (EPA) attenuates the loss in diaphragm specifi c force generation (that is, diaphragm strength) induced by bacterial endotoxin treatment in rats [1].
EPA is found in fi sh oils, along with its derivative docosahexaenoic acid. In the present study, pure EPA was administered orally on two occasions: the fi rst at the same time as endotoxin, and the second 24 hours later (G. Supinski, personal communication). Animals were sacrifi ced 48 hours after the endotoxin administration. EPA was given at a dose of 1 g/kg body weight/day (that is, 2 g/kg). For a 250 g rat, the EPA dose equates to 0.25 g/ day (0.5 g in total). Th is is similar to the amount of EPA that would be consumed by rats fed on a diet containing 5 to 10% by weight as fi sh oil, as is commonly used in experimental studies. On the contrary, the amount of EPA provided here could not be translated directly to humans (70 g/day in a 70 kg individual) and is greatly in excess of amounts provided to patients receiving artifi cial nutrition either parenterally or enterally [2].
In this new study, endotoxin decreased diaphragm specifi c force generation by about 50%, while EPA almost totally prevented this reduction [1]. EPA might attenuate the loss of muscle strength through a variety of actions: EPA has been shown to act as a weak antioxidant [3], to inhibit proteasomes [4,5], to inhibit caspase activation [6] and to reduce infl ammation [7]. In the study of Supinksi and colleagues, EPA did not prevent the caspase activation or oxidative stress pathways in the diaphragm but it did reduce calpain activation [1], suggesting a specifi c eff ect on this proteolytic pathway. Supinski and colleagues thus report a highly novel eff ect of EPA (attenuation of endotoxin-induced loss of respiratory muscle strength) and a novel mecha nism of action (reduced calpain activation) [1]. Th e implication of this work is that administration of EPA may be able to decrease the respiratory, and perhaps other, muscle weakness that accompanies critical illness and sepsis.
Oral fi sh oil provided for a period of time prior to endotoxin administration has been shown to decrease post-endotoxin metabolic perturbations and infl ammation, to improve heart and lung function, and to reduce mortality [8]. Th ese studies provide EPA (and docosahexaenoic acid) in advance of endotoxin treatment, which is not likely to be the best model for the clinical situation, and may favour an eff ect of EPA since it will be incorporated into cells and tissues in advance of the endotoxin stimulus. In Supinski and colleagues' study, EPA was administered at the same time as, and following, endotoxin administration, which is closer to the clinical situation [1]. In critically ill patients in the intensive care unit, parenteral fi sh oil improved lung function and decreased the length of hospital stay [9] while an enteral formula that included fi sh oil improved lung function [10], reduced requirement for ventilatory support [10,11], reduced risk of new organ failures [10][11][12], decreased the intensive care unit stay [10] and reduced mortality [11,12] in patients with acute respiratory distress syn drome [10], with acute lung injury [11] or with sepsis [12].
Th e eff ect on lung function has been linked to a reduction in infl ammation [9,10,13]. Th is latest study, however, suggests that there may be an alternative mecha nism: improved (or maintained) diaphragm function [1]. Th e fi ndings of Supinski and colleagues [1] indicate a rapid eff ect of EPA on the diaphragm that is consistent with the relatively short period of time required to improve lung function [9,10] and to reduce the need for ventilatory support [10,11] seen in these studies in critically ill patients. Th ese latest observations are of signifi cance. It will be important, however, to identify whether EPA administration at a time after the initial insult (in this case, endotoxin) is also protective, since this would be most relevant to the clinical situation, to identify whether doses relevant to the human clinical situation are eff ective, to examine whether this eff ect occurs in patients receiving EPA, and to understand more about the mechanism that underpins this eff ect.